MeiraGTx Holdings plc

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. It operates through the following geographical segments: United States, Ireland, Netherlands, and United Kingdom. Its pipeline includes AAV CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company was founded on March 20, 2015 and is headquartered in New York, NY.

MeiraGTx Holdings plc has rallied over 40% following promising Parkinson's disease data, with significant potential in its Riboswitch platform for gene expression control. The company's diverse pipeline includes gene therapies for salivary gland conditions, neurological disorders, and inherited retinal diseases, with multiple BLAs expected from 2024-2027. Recent strategic deals with J&J and Sanofi have bolstered MeiraGTx's financial position, providing a runway into 2Q26 and highlighting strong investor confidence.

MeiraGTx Holdings: Behind The Recent Rally

MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.74 per share a year ago.

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates

MeiraGTx stock rises 15% as gene therapy candidate betters sham treatment in Parkinson's disease patients.

MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study

MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?

MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease shows promising phase 1/2 results, with significant improvements in UPDRS Part 3 and PDQ-39 scores. The company plans to discuss phase 3 study designs with regulatory agencies in Q4 2024, potentially initiating late-stage studies in 2025. MeiraGTx secured $50 million in funding, including a $30 million equity investment from Sanofi, enhancing its financial stability for future developments.

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.53 per share a year ago.

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates

- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented at the American Academy of Oral Medicine 2024 annual meeting (AAOM) showed meaningful improvements in patient-reported outcomes and saliva production with AAV2-hAQP1 treatment

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

LONDON and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicine company, today announced the pricing of an underwritten offering of 12,500,000 of its ordinary shares at an offering price of $4.00 per share. Gross proceeds to MeiraGTx from the offering are expected to be $50 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by MeiraGTx.

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

AbCellera Biologics

Lexicon Pharmaceuticals

Poseida Therapeutics

Tenaya Therapeutic

Penny stocks represent an interesting investment opportunity.

5 Penny Stocks With 250% Upside in 1 Year According to Wall Street

Bota-vec sale to JNJ/Janssen is complete – cash & future milestones from the deal should carry MeiraGTx through the next catalysts. The partnership with Sanofi strengthens the balance sheet and helps validate technology platforms. MGTX is no longer just an ocular GTx (gene therapy) company - its GTx for radiation-induced xerostomia has a high potential for success.

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:

MeiraGTx to Participate in Upcoming Investor Conferences

LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held from April 16-20, 2024, at the Hyatt Regency Grand Cypress in Orlando, FL.

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.58 per share a year ago.

MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates

- Company aligned with FDA on requirements for ongoing Phase 2 AQUAx2 clinical trial for Grade 2/3 radiation-induced xerostomia to be considered pivotal supporting potential BLA filing

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

Positive results achieved in phase 1/2 MGT009 study using bota-vec for the treatment of patients with XLRP; Patients given this gene therapy achieved meaningful improvement of vision. Enrollment completed in ongoing phase 3 LUMEOS study, using bota-vec for the treatment of patients with XLRP; Potential results could be released end of 2024 or in early 2025. The global Retinitis Pigmentosa market size is expected to reach $20.47 billion by 2029; It is said that 10% to 15% of RP patients have XLRP.

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

The average of price targets set by Wall Street analysts indicates a potential upside of 217.9% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Bet

MeiraGTx (MGTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions

MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.

MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why

The average of price targets set by Wall Street analysts indicates a potential upside of 221.8% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade

- MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) for a total of up to $415 million

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

- Received strategic investment from Sanofi purchasing $30 million of ordinary shares of the Company at a price of $7.50 per share in October 2023

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Sanofi

MeiraGTx Holdings PLC (NASDAQ:MGTX) shares gained more than 25% after it announced Sanofi SA (ADR) (NYSE:SNY), a pharma giant best known for its vaccines, is purchasing 4 million of the gene company's shares at a price of $7.50 per share for a total $30 million investment. MeiraGTx stock was up 25.4% at US$4.64 late morning on Monday, while Sanofi shares gained 3.5% at US$44.63.

MeiraGTx shares take off on $30M investment by Sanofi

Shares of MeiraGTx Holdings PLC MGTX, -4.88% jumped 14% premarket on Monday after the gene therapy company announced that French drugmaker Sanofi SNY, -19.13% has made a $30 million investment.

News for MeiraGTx Holdings plc Stock (MGTX)